- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03763370
Uitgebreid programma voor toegangsverzoeken voor Belantamab Mafodotin (GSK2857916) bij multipel myeloom
209233: Compassionate Use Individual Request Program voor Belantamab Mafodotin bij multipel myeloom 213304: Uitgebreid toegangsprogramma voor Belantamab Mafodotin bij patiënten met recidiverend/refractair multipel myeloom die refractair zijn voor een proteasoomremmer, een immunomodulerend middel en een anti-CD38-antilichaam
Compassionate use access to belantamab mafodotin (GSK2857916) (in combination with bortezomib/dexamethasone or pomalidomide/dexamethasone) for eligible participants with multiple myeloma previously treated with at least 1 prior line of therapy.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) comprised of an afucosylated, humanized Immunoglobulin G1 (IgG1) monoclonal immunoconjugate that binds specifically to B-Cell Maturation Antigen. This program is intended to provide access to belantamab mafodotin (in combination with bortezomib/dexamethasone or pomalidomide/dexamethasone) in patients with Multiple Myeloma (MM) who have received at least 1 prior therapy for multiple myeloma, and whose treating physicians have determined that there is unmet treatment need.
Studietype
Uitgebreid toegangstype
- Individuele patiënten
- Behandeling IND/Protocol
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Specific eligibility criteria must be met, these include:
- There is no satisfactory alternative treatment for the patient including approved standard of care treatments for their multiple myeloma; and
- There is reason to believe that the benefit to the patient using belantamab mafodotin outweighs the risk
- Patient does not qualify for, or is unable to participate in, other ongoing clinical trials
INCLUSION CRITERIA:
-
Written informed consent
-
Diagnosis of multiple myeloma and/or plasma cell dyscrasias and either:
- For combination with bortezomib/dexamethasone; previously treated with at least 1 prior line of MM therapy and must have documented disease progression during or after their most recent therapy OR
- For combination with pomalidomide/dexamethasone; have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and must have documented disease progression during or after their most recent therapy.
-
Able to obtain ophthalmic examinations at baseline, before the next 3 subsequent treatment cycles and as clinically indicated on treatment
-
Contraception requirements
A. Female Participants: A female patient is eligible to participate if one of the following conditions applies:
I. The patient Is not a woman of childbearing potential (WOCBP) OR II. The patient Is a WOCBP and using an effective contraceptive method during treatment with belantamab mafodotin and for 4 months after the last dose. The patient must also have a negative highly sensitive serum pregnancy test within 72 hours of dosing on Cycle 1 Day 1. Please discuss with GSK physician if the patient is pregnant, breast-feeding or planning to have a baby.
B. Male participants with female partners of child-bearing potential are eligible to participate if they agree to use effective contraception during treatment with belantamab mafodotin until 6 months after the last dose
EXCLUSION CRITERIA:
-
If considering combination with bortezomib/dexamethasone intolerant or refractory to bortezomib. If considering combination with pomalidomide/dexamethasone intolerant or refractory to pomalidomide
-
Alanine transaminase (ALT) >2.5x upper limit of normal (ULN).
-
Total bilirubin >1.5xULN; patients with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is ≤1.5xULN.
-
Cirrhosis or current unstable liver or biliary disease per physician assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice.
-
Patients with Hepatitis B will be excluded unless:
- HbcAb positive, HBsAg negative: HBV deoxyribonucleic acid (DNA) undetectable and Antiviral treatment instituted if HBV DNA becomes detectable
- HBsAg positive at screen or within 3 months prior to first dose: HBV DNA undetectable and Antiviral treatment maintained throughout program treatment
-
Patients with positive hepatitis C antibody test result or positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of program treatment unless:
- RNA test negative
- Successful anti-viral treatment followed by a negative HCV RNA test after a washout period of at least 4 weeks
-
Evidence of Active Bleeding requiring intervention
-
Currently Active Graft-versus-host disease (GvHD)
-
Known Hypersensitivity to the active substance or to any of the excipients
-
Previous progression on belantamab mafodotin
-
Active infection requiring treatment
-
Previous participation in DREAMM-7 or DREAMM-8 clinical trials
Studie plan
Hoe is de studie opgezet?
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: GSK Clinical Trials, GlaxoSmithKline
Publicaties en nuttige links
Studie record data
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Vaatziekten
- Hart-en vaatziekten
- Neoplasmata
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Hematologische ziekten
- Lymfoproliferatieve aandoeningen
- Immunoproliferatieve aandoeningen
- Neoplasmata, plasmacel
- Hemostatische aandoeningen
- Paraproteïnemieën
- Bloed eiwit stoornissen
- Hemorragische aandoeningen
- Hemische en lymfatische ziekten
- Multipel myeloom
- Belantamab Mafodotin
Andere studie-ID-nummers
- 209233
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .